Insulin

  • fine 110619SPRINGFIELD – Illinoisans with diabetes will pay less for their prescription insulin, thanks to a new law co-sponsored by State Senator Laura Fine (D-Glenview) that seeks to address soaring prescription drug costs.

    “The cost of insulin has tripled in the past decade, and wages haven’t followed suit. Prescription drug companies shouldn’t be able to burden families with these sky-high costs,” said Fine, who was the measure’s chief co-sponsor in the Senate. “I’m thrilled to help provide some relief to Illinoisans with diabetes.”

    For patients on state-regulated insurance plans, Public Act 101-625 caps the out-of-pocket cost of prescription insulin at $100 for a 30-day supply.

    More than 30 million Americans have diabetes, and 7.4 million Americans require prescription insulin every day to survive, according to the American Diabetes Association. However, the price of insulin has risen sharply in recent years, driving many patients to sacrifice other daily needs to pay for insulin or to ration their supply.

    The legislation makes Illinois the second state to cap prescription insulin co-payments.

    “People with diabetes used to have to choose between paying their bills and paying for insulin,” said Fine. “We’re giving them a little more wiggle room and relieving some of that burden. Hopefully this helps people get their prescription without having to sacrifice other needs.”

    Public Act 101-625 was signed into law on Friday and goes into effect Jan. 1, 2021.

  • koehler 053119SPRINGFIELD – Following the signing of legislation to combat skyrocketing costs of prescription insulin, State Senator Dave Koehler offered the following statement:

    “For far too long, people who need this medication to survive have been forced to make the impossible choice between food and housing or prescription medication,” Koehler (D-Peoria) said. “This life saving medication should be available at a cost that will not break the bank, and with this new law we’re making this a reality for Illinoisans.”

    The price of insulin has drastically increased in the United States in the past several years. According to a 2016 analysis, the price of the drug tripled between 2002 and 2013.

    1.3 million Illinoisans are living with diabetes and rely on insulin to manage their blood sugar levels. Price increases have left many of them struggling to pay for the drug, and at-risk of deadly consequences.

    “This truly is common sense legislation, and I’m incredibly proud to have advocated on its behalf,” Koehler said.

  • insuling signing 012420 ftr

  • stadelman 101119SPRINGFIELD - Amid life-threatening increases in the cost of prescription insulin, Steve Stadelman, a State Senator and father to a diabetic son, voted with fellow lawmakers today to cap insulin copayments. The legislation will cap patients’ out-of-pocket costs for prescription insulin at $100 for a 30-day supply.

    “I have seen the struggle that diabetics face every day,” said Stadelman, a Rockford democrat. “Diabetes is a lifelong affliction for those who have it. It shouldn’t also be the cause of financial stress for their families.”

    There are currently over 30 million Americans who have diabetes, according to the American Diabetes Association. An individual with Type 1 diabetes, a lifelong condition that often begins at birth, will spend an average of $5,705 per year on insulin alone.

    “Without adequate insurance, many people with diabetes can’t afford the insulin they need to survive,” Stadelman said. “Rationing insulin leads to further health problems and more expensive health care costs in the long term. This legislation will provide medical and financial relief for thousands in the Rockford area and across the state of Illinois.”

    The price of insulin has tripled between 2002 and 2013, which has led to many patients rationing their insulin and sacrificing other daily needs to pay for the medication.

    Senate Bill 667 passed with a vote of 48-7 and would make Illinois the second state in the nation to cap prescription insulin co-payments.

  • Manar 101819JOLIET – State Senator Andy Manar (D-Bunker Hill) gathered with fellow state lawmakers and diabetes health advocates in Joliet Friday to urge support for a new measure aimed at reducing the skyrocketing cost of insulin.

    “Absurd insulin costs are making it nearly impossible for some individuals to afford the life-saving medication they need,” Manar said. “It’s time we take a stand on this issue and finally bring some relief for people who are being forced to pay exorbitant prices just to stay alive.”

    Senate Bill 667, introduced by Manar in May, would cap out of pocket insulin expenses at $100 for a 30-day supply.

    Manar was joined by State Sen. Jennifer Bertino-Tarrant (D-Shorewood), State Sen. Pat McGuire (D-Joliet) and State Rep. John Connor (D-Lockport) to push for the legislation’s passage and hear from individuals who have been directly impacted by rising insulin costs.

    According to the American Diabetes Association, more than 30 million Americans have diabetes, 7.4 million of which require prescription insulin every day to survive. However, the increasing costs associated with the medication have led many patients to ration their supply or seek care outside of the country.

    “Insulin is a life-saving prescription drug,” Bertino-Tarrant said. “It is outrageous that drug manufacturers are often placing profit before people. If they are going to utilize greedy profit schemes to make money off of this crucial medication, it is time for the state to intervene.”

    The legislation would make Illinois just the second state in the country to cap out of pocket insulin expenses. Colorado became the first earlier this year.

    The measure has also garnered the support of several advocacy organizations, including the American Diabetes Association, Illinois Alliance for Retired Americans, Illinois State Medical Society, Illinois Pharmacists Association and AARP.

    “AARP Illinois supports this measure on behalf of our 1.7 million members, many of whom have told us about the hardships they face in paying for their prescription drugs,” said State Director Bob Gallo. “We commend Sen. Manar, Rep. Guzzardi, and other legislators for recognizing that everyday Illinois residents are having to make heartbreaking choices about whether to pay for medicine or other basic necessities with their fixed incomes. And we hope that SB 667 will be a stepping stone to getting further reforms that will lower the cost of prescription drugs for everyone.”

    Manar expects to call the bill for a vote during the fall veto session.

  • stadelman 101119CHICAGO – Amid life-threatening increases in the cost of prescription insulin, Steve Stadelman, a state Senator and father to a diabetic son, joined other lawmakers at a press conference this morning to urge the passage of a measure that would cap the medicine’s cost at $100 per 30-day supply.

    “My teenage son is diabetic, and as a parent, I have seen the struggle that diabetics face every day,” said Stadelman (D-Rockford). “Diabetes is a lifelong affliction for those who have it. It should not also be the cause of financial stress for their families.”

    There are currently over 30 million Americans who have diabetes, according to the American Diabetes Association. An individual with Type 1 diabetes, a lifelong condition that often manifests at birth, will spend on average $5,705 per year on insulin alone.

    “Many people do not have adequate insurance, and because of that, they cannot afford the insulin they need to survive,” Stadelman said. “Rationing insulin leads to further health problems and more expensive health care costs in the long run.”

    If passed, Senate Bill 667 would make Illinois the second state to cap prescription insulin co-payments.

    The bill is expected to be heard in the upcoming legislative session that begins Oct. 28.

  • In this edition of the "Senate Showcase" podcast, State Senator Andy Manar (D-Bunker Hill) discusses Senate Bill 667, which would cap insulin costs in Illinois.